3rd Annual
World PK/PD Summit Minimizing Attrition by Optimizing Integration of Pre-Clinical and Clinical Data 27-29 March 2012
Boston, MA

Register now Pricing Download Brochure

Featured Speakers

  • Jianling WangHead of Discovery ADME Cambridge Novartis

  • Kevin BeaumontResearch Fellow & PDM Principal Investigator Pfizer

  • Alaa AhmadDirector, Clinical Pharmacology and Pharmacometrics Bristol-Myers Squibb

  • Immanuel FreedmanManager, Pharmacometrics GSK

Share |
View all...

Are you maximizing PK/PD study integration to minimize drug attrition?

With R&D spending soaring to over the past 5 years, and drug approval plunging 40% in the same time, it is crucial that your drug candidates enter the clinic with as little risk as possible.

The resounding message coming from your peers in the drug development industry is that there needs to be more transparency over the translation of PK/PD data into clinical trial design, and better integration from bench to bedside.

The 3rd Annual World PK/PD Summit will directly address how you can best improve the integration of PK/PD studies and how you can to translate data into early clinical trial design. Attend to hear the likes of Novartis, Pfizer, Johnson & Johnson, Millennium and many more discuss how model-based development can help you decide what molecules to kill early, what candidates to accelerate into the clinic and what dosage to use. 

After the success of our previous meetings, we have worked with your peers to create an agenda that accurately reflect what you need to know in order to leverage your analyses to their full potential and that directly reflects your needs.

So what’s on the agenda at the World PK/PD Summit?

  • How to improve the integration of pre-clinical and clinical studies

  • Translating past data efficiently to ease progress through the clinic

  • Methods of predicting and managing drug-drug interactions

  • How to identify effective biomarkers that best represent efficacy and toxicity

  • Using population PK to optimize dosing regimens in sub-populations

  • Advances in physiologically based modeling and how they can aid the reduction of drug attrition

“An excellent opportunity to find out what other pharma are doing and what’s emerging. Very valuable.”

AstraZeneca

“Strong program, great speakers and a genuine focus on identifying solutions”

Novartis

“A great place to get the very latest information and networking.”

Pfizer

What’s next?

Download the Brochure to see more detail on the topics being covered.

Stay updated by joining the LinkedIn community. Search “The World PK/PD Forum” on LinkedIn.

Something you want to share; white papers, articles or interested in speaking? Then let us know... just email any questions to info@hansonwade.com.

Get the best rates by booking now to ensure your place at this unique meeting - Book online or call +44 203 141 8700.